China urges firms to make generic versions of 34 drugs
pharmafile | June 25, 2019 | News story | Research and Development | China, NHC, generic drugs, generics, patents, pharma
China’s National Health Commission (NHC) has urged generic drugmakers to pick up the production of 34 drugs that are not currently available as generics.
China’s NHC has published a list of 34 patented drugs which it hopes will be taken up by generic drugmakers.
The drugs selected include drugs whose patents have expired, drugs whose patents are close to expiry, drugs that are in short supply and drugs whose manufacturers have voluntarily applied.
The list includes drugs to treat life threatening conditions including AIDS and leukaemia. From now on, similar lists will be published every year.
The list comes after the State Council released guidelines calling on the authorities to take measures to boost the production of generic drugs that are in short supply. It is hoped that generic drugs will prevent shortages and reduce expenditure.
Louis Goss
Related Content
AstraZeneca and Sanofi’s Beyfortus approved in China
AstraZeneca and Sanofi have announced that Beyfortus (nirsevimab) has been approved in China for the …
First patient enrolled in Boan Biotech’s phase 3 trial for Nivolumab in China
Boan Biotech has announced that the first patient has been enrolled in its phase 3 …
AstraZeneca’s Calquence approved in China for chronic lymphocytic leukaemia treatment
AstraZeneca has announced that Calquence (acalabrutinib) has been approved in China for the treatment of …